Overview
Targeted therapy is a class of cancer treatment directed at specific molecular alterations that drive tumor growth, survival, and dissemination, sparing normal cells more effectively than conventional cytotoxic chemotherapy. It includes small-molecule inhibitors of kinases and signaling enzymes, monoclonal antibodies against cell-surface receptors, and agents aimed at intracellular pathways, with selection increasingly guided by molecular diagnostics that identify actionable drivers such as oncogenic kinase fusions, receptor amplifications, and pathway-activating mutations. By interrupting defined biological dependencies, targeted agents can produce durable responses, though acquired resistance and bypass signaling remain central challenges, motivating combination strategies with chemotherapy, radiation, or immunotherapy. The peer-reviewed research in this area covers the molecular rationale and clinical application of targeted approaches, including molecular diagnosis in the management of Thyroid Cancer, pH-sensitive nanomedicine for gynecological cancers, immunotherapy use in pulmonary resection, microRNA expression as a biomarker correlating with PD-L1 status and survival in melanoma, and the evolution of myeloproliferative neoplasms relevant to tyrosine-kinase-directed treatment. Related work explores microRNAs as therapeutic tools in cardiovascular disease. Recurring themes include biomarker-driven patient selection, the integration of nanotechnology and molecular profiling into drug delivery, mechanisms of response and resistance, and the convergence of targeted, immunological, and conventional therapies within precision-oncology frameworks for diverse malignancies.
Research published in this journal
12 peer-reviewed articles, ranked by relevance. Each links to its DOI.
pH-Sensitive Nanomedicine for Treating Gynaecological Cancers
Immunotherapy Usage Has Not Increased Sub-Lobar Pulmonary Resections Despite Reduced Pneumonectomies
Primary Leiomyosarcoma of the Thyroid; a Case Report and a Review of Recent Literature
Complementary and Alternative Treatments for Cancer Prevention and Cure (Part 1)
Lung Cancer and Isolated Adrenal Metastases: Different Disease?
Dynamic MicroRNA-Expression in Plasma of Melanoma Patients Correlates With Progression, PD-L1 Status and Overall Survival
Evolution of Janus Kinase 2 V617F-negative idiopathic myelofibrosis into Philadelphia+ chronic myeloid leukemia
Challenger and Propose Novel Methods and Techniques for Prevention, Prognosis, Diagnosis, Imaging, Screening, Treatment and Management of Lung Cancer
Outcomes of Differentiated Thyroid Cancer Patients Treated with Surgery and Radioactive Iodine at SQCCCRC
Painful Lesions in an HIV-1 Seropositive African Woman.
MicroRNA: New Era for Therapeutic Strategy in Ischaemic Heart Disease
How this research is being cited
The 12 articles above have been cited 15 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
-
2026 · Human Gene
-
Matylda Szewczyk-Łagodzińska et al. · 2023 · Polymers
-
Jaekwon Seok et al. · 2023 · Journal of Translational Medicine
-
2023 · Polymers
-
Sheikh Tanzina Haque et al. · 2022 · Journal of Pharmaceutical Investigation
-
Iman Ehsan et al. · 2022 · Journal of Drug Delivery Science and Technology
-
2022 · Journal of Pharmaceutical Investigation
-
2022 · Elsevier eBooks
A sample of recent works citing this journal's research on Targeted Therapy, linking to each citing work.